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Abstract
Rationale—Cardiomyocyte apoptosis is one of the key events in the development and
progression of heart failure, and a crucial role for ICER (inducible cAMP early repressor) in this
process has been previously reported. ERK5 is known to inhibit cardiac apoptosis after myocardial
infarction (MI), especially in hyperglycemic states, via association with CHIP ubiquitin (Ub)
ligase and subsequent up-regulation of CHIP ligase activity, which induces ICER ubiquitination
and subsequent protein degradation. The regulatory mechanism governing ERK5/CHIP interaction
is unknown.
Objective—We previously demonstrated increased p90RSK activation in the diabetic heart. As a
logical extension of this work, we now investigate whether p90RSK activation inhibits ERK5-
mediated CHIP activation, and subsequently increases ICER levels and apoptosis.
Methods and Results—p90RSK activation inhibits ERK5/CHIP association and CHIP Ub
ligase activity. p90RSK and CHIP share a common binding site in the ERK5 C-terminal domain
(aa571-807). Overexpression of either p90RSK or an ERK5 fragment (aa571-807) inhibits ERK5/
CHIP association, suggesting that p90RSK and CHIP competes for ERK5 binding and that
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p90RSK activation is critical for inhibiting ERK5/CHIP interaction. We also identified ERK5-
S496 as being directly phosphorylated by p90RSK, and demonstrated that an ERK5-S496A
mutant significantly impairs Angiotensin II-mediated inhibition of CHIP activity and subsequent
increase in ICER levels. In vivo, either cardiac specific depletion of ERK5 or overexpression of
p90RSK inhibits CHIP activity and accelerates cardiac apoptosis after MI--a phenomenon fully
reversible by activating ERK5.
Conclusion—These data suggest a role for p90RSK in inhibiting CHIP activity and promoting
cardiac apoptosis through binding to and phosphorylation of ERK5-S496.
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INTRODUCTION
Diabetes mellitus (DM) is an independent risk factor for both mortality and morbidity after
myocardial infarction (MI)1, 2. Previously, we have reported that activation of ERK5, an
atypical mitogen activated protein kinase with transcriptional activity3-6, inhibits apoptosis
and left ventricular (LV) dysfunction in DM mice following MI. Sustained elevation of
inducible cAMP early repressor (ICER), a pro-apoptotic transcriptional repressor7, 8, favors
apoptosis through inhibition of the cAMP response element binding protein (CREB)-
mediated transcription and down-regulation of Bcl-29, 10. The protein level of ICER is
regulated by CREB-dependent ICER gene transcription as well as proteasome-dependent
ICER protein ubiquitination and degradation11. We reported that ICER levels were
significantly increased in diabetic mice after MI (DM+MI), and this increase in ICER levels
was blunted in transgenic mice expressing a cardiac-specific constitutively active form of
MEK5α (CA-MEK5α-Tg)12. This finding provides a mechanistic framework for
understanding the cardio-protective action of ERK5 in DM + MI mice via downregulation of
ICER levels and inhibition of apoptosis.
In a subsequent study we demonstrated that ubiquitination was a critical regulatory
mechanism linking ERK5 activation and ICER reduction in DM mice. ERK5 positively
regulated chaperone-dependent E3 ubiquitin (Ub) ligase CHIP (carboxyl terminus of Hsp70-
interacting protein)-mediated ICER ubiquitination and subsequent protein degradation. This
down-regulation of ICER levels leads to maintaining Bcl-2 at high levels, and protects cells
from apoptosis. Our studies showed that cardiac CHIP Ub ligase activity was significantly
decreased after DM + MI and this decrease was rectified in CA-MEK5α-Tg mice13.
However, the regulatory mechanism underlying this reduction of CHIP Ub ligase activity in
DM + MI mice and how ERK5 activation reversed this phenomenon remains unclear.
In this study, we show that the ERK5-CHIP module is one of the major targets of p90RSK
in diabetic hearts. Our data strongly suggest that the activation of p90RSK abrogates ERK5-
mediated CHIP Ub ligase activation, and accelerates apoptosis and cardiac dysfunction in
the DM+MI condition.
METHODS
Additional information regarding animals, antibodies and reagents, plasmids, adenovirus
construction, cell culture, mammalian two-hybrid analysis, immunoprecipitation, western
blotting, p90RSK in vitro kinase assay, in vitro ubiquitination assay with GST-ICER,
permanent coronary ligation surgery, streptozotocin (STZ) injection, apoptosis assay,
echocardiographic analysis, LC-MS/MS analysis of ERK5 phosphorylation by p90RSK, and
statistics can be found in the Online Data Supplement at http://circres.ahajournals.org.
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Angiotensin II upregulates the ICER protein levels and promotes apoptosis of
cardiomyocytes via p90RSK activation
Angiotensin II (Ang II) plays a pivotal role in the exacerbation of heart failure in patients
with diabetes after MI14-16. In these patients the ICER protein levels and apoptosis in
cardiomyocytes are enhanced17, 18, and p90RSK is also activated19. p90RSKs are a family
of serine/threonine kinases, activated by various stimuli including ischemia20, 21, reactive
oxygen species (ROS)22-25, Ang II26-28, and DM24. Since ICER is important in the
regulation of cardiomyocyte apoptosis12, we have examined whether p90RSK modulates
apoptosis via regulation of the ICER protein level. First, we confirmed that Ang II activated
p90RSK in cardiomyocytes (Online Figs. IA and IB). Similarly, high glucose (25 mM) also
activated p90RSK, whereas mannitol (25 mM), which served as a hyperosmolar control, did
not (OnlineFigs. IC and ID).
Next, we investigated the involvement of p90RSK activation in cardiomyocyte apoptosis as
assayed by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling) staining. When cardiomyocytes were treated with Ang II, both ICER levels (Figs.
1A and 1B) and the number of TUNEL-positive cells (Figs. 1E and 1F) increased. However,
these increases were inhibited in cells transduced by an adenovirus expressing dominant
negative p90RSK (Ad-DN-p90RSK) (Figs. 1A and 1B and Figs. 1E and 1F).
In addition to overexpressing dominant negative p90RSK, we also used 1-(4-amino-7-(3-(2-
methoxyethylamino) proxyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-fluoroethanone
(FMK-MEA) which is a water-soluble derivative of the previously reported
fluoromethyllketone, a selective p90RSK inhibitor.29, 30. Ang II-induced increase in the
ICER levels and apoptosis assayed by cleaved caspase 3 expression were significantly
inhibited in cardiomyocytes treated by FMK-MEA (Figs.1C and 1D), also supporting the
obligatory role of p90RSK activation in these Ang II-mediated effects. We confirmed that
Ang II-mediated p90RSK activation was significantly inhibited by Ad-DN-p90RSK
transduction and FMK-MEA treatment (Online Fig. II). Furthermore, we performed the
converse experiment using Ad-WT-p90RSK and found higher ICER levels in
cardiomyocytes (OnlineFigIIIB), also confirming an obligatory role for p90RSK in
regulating ICER levels.
Activation of p90RSK reduces CHIP Ub ligase activity induced by Ang II in vitro and after
myocardial infarction in diabetic mice in vivo
ERK5-CHIP association is critical for the up-regulation of CHIP Ub ligase activity, leading
to the ubiquitination and subsequent proteosomal degradation of ICER13. Since p90RSK
activation was crucial for an Ang II-mediated increase in ICER levels, we investigated
whether p90RSK could negatively regulate CHIP Ub ligase activity and thereby stabilize the
ICER protein. To detect CHIP Ub ligase activity, we performed an in vitro ubiquitination
assay using a GST-ICER fusion protein as a substrate13. CHIP Ub ligase activity was
significantly decreased after Ang II stimulation, and transduction with Ad-DN-p90RSK
significantly inhibited this phenomenon (Figs. 2A and 2B).
Next we investigated whether p90RSK activation could regulate ICER mRNA expression.
As shown in Online Fig. IIIA, we found that Ang II increased ICER mRNA expression.
However, we could not detect any inhibition of ICER mRNA expression by Ad-DN-
p90RSK transduction. These data suggested that p90RSK activation regulates ICER levels
at the post-transcriptional rather than the transcriptional level. Since CHIP Ub ligase activity
requires ERK5-CHIP interaction13, and since Ang II regulates this process by activating
p90RSK, we examined whether Ang II-mediated p90RSK activation could regulate ERK5-
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CHIP interaction. In quiescent cardiomyocytes, ERK5 activity regulates the association of
ERK5 with CHIP 13. Indeed, we found that the ERK5-CHIP association was significantly
decreased by stimulation of cardiomyocytes with Ang II ( s. 2C and 2D) and Ad-DN-
p90RSK transduction blocked this decrease in cells treated with Ang II (Figs. 2C and 2D).
These results indicated a key role for p90RSK in the reduction of ERK5-CHIP association,
and subsequent inhibition of CHIP Ub ligase activity in cells stimulated with Ang II.
To explore the role of p90RSK activation in the reduction of CHIP Ub ligase activity in
vivo, we utilized the cardiac-specific DN-p90RSK-Tg mice. These mice showed relative
resilience to cardiac ischemia/reperfusion injury31, therefore we examined the effects of
inhibiting p90RSK in diabetic mice after MI. The cardiac function of DN-p90RSK-Tg mice
was unaltered 31, and the ICER levels in these transgenic were similar to that of non-
transgenic littermate control (NLC) sham operated mice (Online Fig. IVA). Mice were
rendered diabetic by intraperitoneal injection of streptozotocin (STZ). On day 7 after STZ
injection, both NLC and DN-p90RSK-Tg mice showed elevated random blood sugar (BS)
levels with similar body weight (Online Fig. VB). We have previously shown that
preoperative insulin-treatment of STZ-injected mice stabilizes cardiac function after MI,
suggesting myocardial derangement in diabetic mice after MI is a function of hyperglycemia
rather than a toxicity artifact of STZ32. DN-p90RSK-Tg diabetic mice had improved
survival after MI compared to that of NLC mice (Online Fig. VA). One week after MI, the
LV weight/TL (tibial length) and lung weight/TL ratios were increased in NLC mice (Online
Figs. VC and VD), whereas these parameters were reduced in DN-p90RSK-Tg mice
(OnlineFig. VD). Echocardiography performed one week after MI showed increased left
ventricular end diastolic diameter (LVEDd) and left ventricular end systolic diameter
(LVESd) in diabetic NLC mice with a concomitant decrease in fractional shortening (FS)
and ejection fraction (EF) (Online Fig. VE) compared to sham-operated non-MI controls. By
contrast, we found that these MI-induced cardiac effects were attenuated in DN-p90RSK-Tg
mice (Online Fig. VE).
The role of p90RSK activation in regulating CHIP Ub ligase activity, subsequent ICER
levels and cardiomyocyte apoptosis in vivo were examined. As shown in Figs. 3A, 3D, and
S6, CHIP Ub ligase activity was significantly decreased one week after MI in diabetic NLC
mice but not in diabetic DN-p90RSK-Tg mice (Figs. 3A and 3D and Online Fig. VI). Since
CHIP Ub ligase activity regulates ICER protein stability in heart failure 12, 13, we examined
the ICER protein level as well as the abundance of downstream ICER mediators, such as
Bcl-210 and SERCA233. In NLC mice, we found increased ICER levels and a concomitant
reduction in Bcl-2 expression after MI in diabetic mice and this was rescued in DN-
p90RSK-Tg diabetic mice after MI (Figs. 3A, 3B and 3D). SERCA2 expression was also
reduced in NLC diabetic mice after MI. However, the reversal of this effect in DN-p90RSK
diabetic mice after MI is less obvious (Figs. 3B and 3D). Interestingly, the level of ERK5
phosphorylation at T218 and Y220 was decreased slightly in DN-p90RSK diabetic mice
after MI (Fig. 3C), suggesting a role for activated p90RSK in phosphorylating ERK5 T218/
Y220-the same residues phosphorylated by MEK5 responsible for ERK5 activation.
TUNEL-positive cells significantly increased in diabetic NLC mice after MI when compared
with sham controls (Online Figs. VF and VG), supporting the known role of cellular
apoptosis in the development of heart failure34. Notably, reduced incidence of apoptosis was
found in diabetic DN-p90RSK-Tg mice after MI (Online Figs. VF and VG), suggesting a
functional consequence for p90RSK activation in promoting cardiac apoptosis after MI in
diabetic animals.
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p90RSK activation inhibits ERK5-CHIP association via competitive binding with ERK5 and
direct phosphorylation of ERK5-S496
Upon activation, ERK5 exerts its cardio-protective effect by promoting ERK5-CHIP
binding, which increases CHIP Ub ligase activity13. Since there is a role for p90RSK
activation in Ang II-mediated disruption of ERK5-CHIP binding and subsequently reduction
of CHIP Ub ligase activity (Figs. 1 and 2), we investigated how p90RSK regulates ERK5-
CHIP association. To determine the protein domain of ERK5 responsible for the p90RSK-
ERK5 and ERK5-CHIP interaction, we generated three truncated ERK5 fragments and
evaluated their association with p90RSK (Fig. 4A) and CHIP (Fig. 4B) using a mammalian
two-hybrid assay. A plasmid containing GAL4-DBD (DNA binding domain) and the full-
length p90RSK (Fig. 4A) or CHIP (Fig. 4B) were constructed in the pBIND vector;
plasmids to express VP16-ERK5 (full-length or truncated forms) were constructed in the
pACT vector. Constitutively active MEK5α (CA-MEK5α) induces forced activation of
ERK5 and significantly increases ERK5-CHIP association by decreasing the inhibitory
effect of the NH2-terminal kinase domain of ERK5. This ERK5-CHIP association at the
helical linker domain of CHIP is fundamental for increasing CHIP Ub ligase activity13.
Therefore, we examined the effect of CA-MEK5α expression on the association of ERK5
and CHIP. The mammalian two-hybrid assay demonstrated that the NH2-terminal region of
ERK5 (aa1-148) and the COOH-terminal region of ERK5 (aa571-807) associate with CHIP
(Figs. 4A and 4B). The latter site overlaps with the p90RSK binding site.
To examine whether the wild type p90RSK and the ERK5 fragment (ERK5-Fr, aa571-807)
alter ERK5-CHIP association in vitro, we utilized an over-expression system. Since CHIP
binding site is within the ERK5 aa571-807 region, we focused on ERK5-Fr (aa571-807).
ERK5-CHIP binding was increased by CA-MEK5α (Fig. 4C, lane 3). Over-expression of
both wild type p90RSK and ERK5-Fr inhibited ERK5-CHIP association (Fig. 4C, lane 5-6
and Online Fig. VIIA, B), suggesting that the ability of WT p90RSK to inhibit ERK5-CHIP
association was due to competition between p90RSK and ERK5 for the same binding site on
CHIP (Fig. 8E).
Since p90RSK inhibits ERK5-CHIP association via competitive binding with ERK5, we
have investigated whether Ang II-mediated p90RSK activation is required for p90RSK-
ERK5 association in cardiomyocytes. Ang II increased p90RSK-ERK5 binding, and this
was significantly inhibited by FMK-MEA (Figs. 4D and 4E). As p90RSK activation induced
by Ang II increased p90RSK-ERK5 binding, we determined the role of p90RSK activation
in ERK5-CHIP binding. Wild type p90RSK but not DN-p90RSK completely inhibited
ERK5-CHIP association (Fig.4C, lane 4-5, and Online Fig.VIIC and D), supporting the role
of p90RSK activation in increased p90RSK-ERK5 association as well as decreased ERK5-
CHIP association. Based on these results, we reasoned that since Ang II induced p90RSK,
but not ERK5, activation (Online Fig. VIII), the regulation of ERK5-CHIP binding mediated
by p90RSK activation most likely occurs by a process that requires direct interaction of the
two without ERK5 enzymatic activity being activated (Fig. 8E).
Since p90RSK can associate with ERK5, we asked whether p90RSK directly
phosphorylated ERK5 and as a consequence inhibited CHIP Ub ligase activity. To test this
possibility, we performed an in vitro kinase assay by incubating recombinant p90RSK with
GST-tagged-ERK5 fragments and found that p90RSK phosphorylated two ERK5 fragments
(aa401-600 and aa601-816) (Fig. 5A). In addition, liquid chromatography coupled with
tandem mass spectrometry (LC-MS/MS) analyses identified ERK5-S496 as being directly
phosphorylated by p90RSK (Figs. 5B and 5C). To determine whether ERK5-S496
phosphorylation is involved in the Ang II-mediated reduction of CHIP Ub ligase activity in
cardiomyocytes, we generated an adenovirus expressing the ERK5-S496A mutant (Ad-
ERK5-S496A). Cardiomyocytes were transduced with Ad-ERK5-S496A, Ad-ERK5-WT, or
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Ad-LacZ, followed by Ang II stimulation. Cell lysates were then subjected to an in vitro
CHIP ubiquitination assay using a GST-ICER fusion protein as a substrate. Ang II inhibited
CHIP Ub ligase activity in cardiomyocytes transduced by Ad-LacZ or Ad-ERK5-WT. In
contrast, Ad-ERK5-S496A transduction abolished this inhibitory effect on CHIP Ub ligase
activity (Figs. 5D and 5E). In addition, the Ang II-mediated increase in ICER levels was
significantly inhibited in cardiomyocytes overexpressing Ad-ERK5-S496A mutant, but not
in those expressing the Ad-ERK5-WT or Ad-LacZ (Figs.5F and 5G). These findings
indicate that p90RSK-mediated ERK5-S496 phosphorylation is required for inhibiting CHIP
Ub ligase activity (Figs. 8D and 8E).
Cardiac-specific ERK5 knockout mice (ERK5-CKO) showed reduced CHIP Ub ligase
activity after MI
To corroborate the necessity of ERK5 activation in increasing CHIP Ub ligase activity and
subsequent reduction of ICER, we utilized ERK5-CKO. Since ERK5 activation is cardio-
protective13 and ERK5-CKO mice displayed significantly increased levels of cardiac
dysfunction after MI under the non-DM condition (Figs. 6A, 6B and 6C), we subjected the
mice to MI only. No basal cardiac abnormality was found in ERK5-CKO mice as we
reported previously35, and no increase in ICER levels was observed (Online Fig. IVB). After
MI, ERK5-CKO mice showed a significant reduction in CHIP Ub ligase activity, and an
increase in ICER levels (Figs. 6F and 6G) compared to the NLC mice. As expected, the
ERK5-CKO mouse hearts showed a significant increase in the number of TUNEL-positive
cardiomyocytes compared with the NLC group (Figs. 6D and 6E). These data further
confirmed the importance of ERK5 in regulating CHIP Ub ligase activity and subsequent
ICER levels and apoptosis in vivo (Fig. 8D). Since a difference in the infarct size may
correlate with post-MI cardiac dysfunction, we compared the permanent coronary ligation-
mediated infarct size between NLC (C57BL/6) and ERK5-CKO mice. As shown in Online
Fig. IX, we did not find any difference in the infarct size among these groups, although we
found significant cardiac dysfunction and an increase in lung weight/TL in ERK5-CKO
mice.
The reduction of CHIP Ub ligase activity and increased ICER levels were observed in WT-
p90RSK-Tg mice after MI but were significantly inhibited in WT-p90RSK-Tg/constitutive
active (CA) MEK5α double transgenic mice
Thus far, we have shown the critical role of the p90RSK-ERK5 module in CHIP Ub ligase
activity and ICER levels in vitro, but the role of this module in vivo remains unclear. To
clarify the function of the p90RSK-ERK5 signaling cascade in vivo, we crossed WT-
p90RSK-Tg mice with those expressing constitutive active MEK5α (CA-MEK5α-Tg) to
generate double transgenic mice (Double-Tg). Cardiac function is normal in CA-MEK5α-Tg
and WT-p90RSK-Tg mice at 8-12 weeks of age as we previously described36, 37. Double-Tg
also shows normal cardiac function (FS% = 67.7 ± 3.7, n = 3). No increase in ICER levels
was observed in WT-p90RSK-Tg or Double-Tg mice (Online Fig. IVA).
Non-diabetic mice were subjected to a simple MI. Following MI, the mortality of WT-
p90RSK-Tg mice was significantly greater than NLC mice. The mortality of Double-Tg was
similar to NLC mice (Fig. 7A). There was no difference in body weight among the three
groups (Fig. 7B). One week after MI, the LV weight/TL and lung weight/TL ratios were
higher in WT-p90RSK-Tg mice compared to NLC mice (Figs. 7C and 7D) but lower in
Double-Tg mice compared to WT-p90RSK-Tg mice (Figs. 7C and 7D). Myocardial
contractile function as assessed by echocardiography was diminished in WT-p90RSK-Tg
mice compared to NLC following MI (Fig. 7E). Myocardial contractile function as assessed
by echocardiography was preserved in Double-Tg mice (Fig. 7E). We previously reported
that CA-MEK5α-Tg mice develop contractile dysfunction one week after simple MI32. In
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contrast, we found that activation of ERK5 by CA-MEK5α could reverse the detrimental
effect of p90RSK activation on cardiac function after a simple MI, consistent with the idea
that p90RSK activation accelerates cardiac dysfunction and heart failure after MI, possibly
via inhibiting ERK5 activity. We also assessed the infarct size after permanent coronary
ligation in NLC (FVB) mice, in diabetic mice, and in Double-Tg mice. As shown in Online
Fig.IX, we found no difference in infarct size among these three groups. However, we noted
significant cardiac dysfunction and increase of lung weight/TL in diabetic mice after MI.
These data suggest that the major difference in cardiac dysfunction observed after one week
of MI stems from cardiac remodeling in the surrounding, non-infarcted area rather than
simply from infarct expansion.
Next, we investigated the involvement of CHIP Ub ligase activity in regulating ICER levels.
Compared to the sham NLC mice, WT-p90RSK-Tg mice have reduced CHIP Ub ligase
activity one week after MI. In contrast, no decrease in CHIP Ub ligase activity was observed
in Double-Tg mice (Figs. 8A and 8C). The increase in ICER level and concomitant
reduction in Bcl-2 expression in WT-p90RSK-Tg mice were also detected, and these
changes were mostly reversed in Double-Tg mice (Figs. 8A, 8B and 8C). Similar to NLC
diabetic mice after MI (Figs. 3B and 3D), SERCA2 expression was also reduced in WT-
p90RSK-Tg mice after MI (Figs. 8B and 8C). However, restoration of SERCA2 expression
in Double-Tg mice after MI was observed (Figs. 8B and 8C), contrasting what was observed
DN-p90RSK diabetic mice after MI (Figs. 3B and 3D).
Finally, WT-p90RSK-Tg mice have increased apoptosis one week after MI compared with
sham NLC mice, and this phenomenon was reversed in Double-Tg mice (Figs. 7F and 7G).
Taken together, ERK5 activation suppresses p90RSK-mediated cardiac apoptosis after MI in
vivo.
DISCUSSION
In this study, we demonstrated a critical role for p90RSK activation in the reduction of
CHIP Ub ligase activity and subsequent increase in the ICER protein levels (Figs. 8D and
8E). p90RSK activation promotes its association with ERK5 and phosphorylates it at S496.
This phosphorylation appears to be a necessary and sufficient step in the ability of p90RSK
to promote the dissociation of the ERK5-CHIP complex, which leads to reduced CHIP Ub
ligase activity. The physiologic significance of p90RSK activation in diabetic mice after MI
lies in its ability to decrease CHIP Ub ligase activity. This mechanism is reversed in diabetic
DN-p90RSK-Tg mice, which show increased CHIP Ub ligase activity and recovery of
cardiac function.
Depletion of ERK5 inhibited CHIP Ub ligase activity and enhanced ICER levels after MI,
suggesting a causal role of ERK5 in controlling CHIP Ub ligase activity and subsequent
ICER stability. Supporting the role of ERK5 as a negative regulator of p90RSK-mediated
CHIP Ub ligase inhibition, we demonstrate that diabetic WT-p90RSK-Tg mice exhibit
diminished CHIP Ub ligase activity after MI, but that co-expressed CA-MEK5α in Double-
Tg mice leads to restoration of CHIP Ub ligase activity, and prevents cardiac dysfunction, at
least in part by preventing myocardial apoptosis.
Our studies focus on defining the molecular mechanism of cardiac dysfunction after MI,
which is a prevalent but poorly understood consequence of diabetes. Therefore, we
established a diabetic model of MI in which post-MI biochemical and physiological
sequelae could be carefully examined in the immediate post-MI period 32. We observed that
p90RSK activation was significantly increased in DM. Consistent with our previous work in
WT-p90RSK-Tg mice, we see cardiac dysfunction and significant fibrosis after 8 month of
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age--a phenotype similar to that seen in diabetic cardiomyopathy37. Furthermore, we found
that DN-p90RSK-Tg mice do not suffer the same degree of cardiac dysfunction after MI in a
diabetic model, supporting an important role for p90RSK in the development of cardiac
dysfunction after MI in diabetes. The ability of p90RSK activation to decrease functionality
of the ERK5-CHIP module suggests that cardiac-specific ERK5 knockout mice (ERK5-
CKO) mimic the deleterious effect of diabetes on the heart. Therefore, we modeled MI only
in WT-p90RSK-Tg (Fig.8) and ERK5-CKO mice (Fig.6). As mentioned above, we found
that CHIP Ub ligase activity after MI was inhibited in ERK5-CKO mice compared with
NLC mice. We also observed that CHIP activity in the sham operation group is much lower
in C57BL/6 than FVB mice. The background of ERK5-CKO mice is C57BL/6, while the
background of DN-p90RSK-Tg, WT-p90RSK-Tg, and Double-Tg is FVB. Therefore, this
may explain why C57BL/6 mice are much more sensitive to MI than FVB strain and show
much higher mortality after MI surgery. Further investigation will be necessary to clarify
this issue.
Ranganathan et al. reported that the COOH-terminal domain of the D motif of p90RSK is an
ERK5 binding site and that p90RSK activation was required for full association between
p90RSK and ERK538. Consistent with this report, in our present study, we found that
p90RSK activation is a key event in disrupting ERK5-CHIP interaction by: 1) competitive
binding of p90RSK to ERK5 causing displacement of CHIP from ERK5, and 2)
phosphorylation of ERK5 at S496. Forced activation of ERK5 induced by IGF-1 or CA-
MEK5α inhibits the association of p90RSK with ERK5. In addition, activated ERK5
significantly increases ERK5-CHIP association by relieving the inhibitory effect of the NH2-
terminal kinase domain of ERK5 (Figs. 8D and 8E). ERK5-CHIP association at the helical
linker domain of CHIP is critical for increasing CHIP Ub ligase activity13. In support of this,
the elevation of ERK5 activity in Double-Tg mice reversed the inhibitory effect of p90RSK
activation on CHIP Ub ligase activity. Taken together, our data demonstrate that p90RSK
activation influences the ability of its own COOH-terminus docking domain to bind ERK5
and phosphorylate residue S496. The p90RSK-ERK5 interaction and ERK5-S496
phosphorylation disrupt ERK5-CHIP association and decrease CHIP Ub ligase activity
(Figs. 8D and 8E). It is possible that the association between p90RSK and ERK5 is
necessary for p90RSK to phosphorylate S496 ERK5, or that p90RSK-mediated S496
phosphorylation of ERK5 leads to dissociation of p90RSK and ERK5. To determine which
of these possibilities is true will require further investigation.
Our data show that p90RSK activation regulates ICER protein stability by regulation of
CHIP Ub ligase activity. In support of this, 1) an ERK5-S496A mutant significantly inhibits
Ang II-mediated reduction of CHIP Ub ligase activity and subsequent increase in ICER
levels (Fig.5), 2) CHIP is critical for ERK5-mediated decrease in ICER level13, and 3)
depletion of CHIP increases ICER stability13. CHIP activity can regulate a variety of
molecules including FOXO139, ASK140, and p5341, 42, and we cannot exclude the
possibility that p90RSK can regulate the expression of these molecules via CHIP, and that
dysregulation of these molecules contribute to cardiac dysfunction. In addition, p90RSK and
ERK5 can also regulate proteins with CHIP and ICER-independent mechanism including
Na+/H+ exchanger28, renin-angiotensin system37, 43, and PPARs activities5, 44. Further
investigation is necessary to clarify the role of these molecules in p90RSK/ERK5-mediated
cardiac dysfunction, especially in DM, both in vitro and in vivo.
Naito et al. reported that CHIP expression was decreased with concomitant upregulation of
p53 expression within four days following MI42. In our study there was no significant
decrease in CHIP expression or increase in p53 expression at seven days following MI in
diabetic mice (data not shown). Instead, we found a significant decrease in CHIP Ub ligase
activity in our diabetic mice following MI. The regulatory mechanism responsible for the
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down-regulation of CHIP expression was not identified in the previous studies42. Our
present study suggests a role for p90RSK activation in regulating ERK5-CHIP association
and subsequent CHIP Ub ligase activation. Whether through an early decrease in CHIP
expression or a later decrease in its Ub ligase activity, the net effect is promotion of the pro-
apoptotic milieu contributing to poor functional recovery in diabetic mice following MI.
Based on our results on the role of p90RSK-ERK5-CHIP described in our current work,
ERK5 activation may reverse the decrease in Ub ligase activity and ameliorate cardiac
dysfunction after MI in DM hearts.
Lastly we close by commenting on the protective function of ERK5 after MI with or without
superimposed DM. In this study we showed that cardio-protective effect of ERK5 activation
is particularly significant after MI in the context of DM. Previously, we reported that the
cardiac function did not improve after one week of MI in the absence of DM in CA-
MEK5α-Tg mice compared with NLC mice 32. These data suggest that ERK5 activation
does not have a significant cardio-protective role in our MI model one week after permanent
ligation. Although the role of ERK5 activation in cardiac remodeling after permanent
ligation is limited, we found that cardiac protection was enhanced in hyperglycemic CA-
MEK5α-Tg mice 32, suggesting that ERK5 activation has a significant role in DM after MI
rather than being a consequence of MI per se, at least during the acute phase (within one
week) after MI.
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Non-standard Abbreviations and Acronyms
Ad-DN-p90RSK adenovirus expressing dominant negative form of p90RSK
Ang II angiotensin II
BS random blood sugar
CA-MEK5α-Tg cardiac specific constitutively active form of MEK5α transgenic mice
CHIP carboxyl terminus of Hsc70-interacting protein
CREB cAMP response element binding protein
CTD C-terminal kinase domain
DM diabetes mellitus
DM + MI DM mice after myocardial infarction
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Double-Tg double transgenic mice crossing wild-type p90RSK-Tg (WT-
p90RSK-Tg) and CA-MEK5α-Tg
EF ejection fraction
ERK5 extra-cellular signal-related kinase 5





ICER inducible cAMP early repressor
IGF-1 insulin growth factor-1
LC-MS/MS liquid chromatography coupled with tandem mass spectrometry
LV left ventricle
LVEDd left ventricular end diastolic diameter
LVESd left ventricular end systolic diameter
MI myocardial infarction
NLC non-transgenic littermate control
p90RSK p90 ribosomal S6 kinase
ROS reactive oxygen species
STZ streptozotocin
TL tibial length
TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling
Ub ubiquitin
WT-p90RSK-Tg cardiac specific wild-type p90RSK transgenic mice
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• Diabetes mellitus (DM) is an independent risk factor for both mortality and
morbidity following myocardial infarction (MI) Induction of inducible cAMP
early repressor (ICER), a proapoptotic transcriptional repressor, accelerates
myocyte apoptosis and subsequent cardiac dysfunction in DM mice after MI.
• Activation of ERK5 positively regulates chaperone-dependent E3 ubiquitin (Ub)
ligase CHIP (carboxyl terminus of Hsp70-interacting protein)-mediated ICER
ubiquitination and subsequent protein degradation, which protects
cardiomyocytes from apoptosis.
• .
What new information does the article contribute?
• ERK5-CHIP module is one of the major targets of p90RSK in diabetic hearts.
• Depletion of ERK5 inhibits CHIP Ub ligase activity and increases ICER levels
after MI.
• Diabetic wild type p90RSK transgenic mice exhibit diminished CHIP Ub ligase
activity after MI. However, when these mice co-express a constitutively active
form of MEK5α in double transgenic mice, CHIP Ub ligase activity is restored,
also restoring cardiac dysfunction, at least in part by preventing myocardial
apoptosis.
• The activation of p90RSK abrogates ERK5-mediated CHIP Ub ligase
activation, and accelerates apoptosis and cardiac dysfunction in the DM+MI
condition.
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Summary of the Novelty and Significance
DM reduces survival after MI primarily due to acceleration of heart failure. We have
found that the activation of p90RSK abrogates ERK5-mediated CHIP Ub ligase
activation, and accelerates apoptosis and cardiac dysfunction in the DM+MI condition.
Our data demonstrate that p90RSK activation influences the ability of its own COOH-
terminus docking domain to bind ERK5 and phosphorylate residue S496. The p90RSK-
ERK5 interaction and ERK5-S496 phosphorylation disrupt ERK5-CHIP association and
decrease CHIP Ub ligase activity. The regulatory mechanism responsible for the down-
regulation of CHIP expression after MI has not yet been identified. Our present study
suggests a role for p90RSK activation in regulating ERK5-CHIP association and
subsequent CHIP Ub ligase activation. either through an early decrease in CHIP
expression or a later decrease in its Ub ligase activity The net effect is promotion of the
pro-apoptotic milieu contributing to poor functional recovery in diabetic mice following
MI. ERK5 activation may reverse the decrease in Ub ligase activity and ameliorate
cardiac dysfunction after MI in DM hearts. Understanding the role and molecular
mechanisms how p90RSK targets ERK5-CHIP ubiquitin E3 ligase activity should
provide insights into mechanisms contributing to poor cardiac recovery after MI in DM
and possibly reveal a novel therapeutic target.
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Figure 1. Ang II induced ICER expression and apoptosis via p90RSK activation
(A) Cardiomyocytes were transduced with adenovirus containing either dominant negative
form of p90RSK (Ad-DN-p90RSK) or LacZ (Ad-LacZ) as a control (MOI = 20) for 3 h.
They were then stimulated with Ang II (100 nM and 200 nM) for 24 h. ICER, p90RSK and
tubulin were detected by Western blotting with each specific antibody. (B) ICER band
intensities were quantified (Fujifilm Image Gauge 4.0) and normalized relatively to tubulin
band intensity. Results are expressed as fold increase in Ang II-treated compared to the
untreated group. * p<0.05, compared to untreated control, mean±S.D., n=3. (C)
Cardiomyocytes were stimulated with Ang II for 24 h after 3 h of FMK-MEA pre-treatment,
and Western blotting was performed with each specific antibody. (D) ICER and cleaved
caspase-3 band intensities are shown relatively to the tubulin band intensity at each point.
Shown is mean±S.D. (n=3). *p<0.05 , compared to the vehicle control. (E) Cardiomyocytes
were transduced with Ad-DN-p90RSK or Ad-LacZ as in (A) and stimulated with AngII (200
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nM) for 24 h, and processed for TUNEL staining. Representative pictures of TUNEL
(top),α-actinin (second row), DAPI (third row), and merged (bottom) staining. 40X
objective lens. Scale bars: 40 μm. (F) Bar graphs showing percentage of TUNEL positive
cells (total of 400-600 cells counted). **p<0.01, *p<0.05, mean±S.D., n=3.
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Figure 2. p90RSK inhibited CHIP Ub ligase activity and ERK5-CHIP association
(A) Ang II inhibited CHIP Ub ligase activity. Cardiomyocytes were transduced with either
Ad-DN-p90RSK or Ad-LacZ for 24 h, followed by stimulation with Ang II (200 nM) for
indicated times. Immunoprecipitated CHIP was subjected to an in vitro ubiquitination assay
to determine CHIP Ub ligase activity using GST-fused ICER protein as a substrate (lane
1-4). The expression of Flag-tagged DN-p90RSK, CHIP, and tubulin was detected by
Western blotting with each specific antibody. In vitro Ub ligase assay of GST-ICER with the
Ub conjugation system and immunoprecipitates with IgG control (lane 7), and in vitro Ub
ligase assay with GST only (lane 6) or without any GST substrate (lane 5) with the Ub
conjugation system and immunoprecipitates with CHIP Ab (lane 1-6) were also shown.
Immunobloting with anti-CHIP (2nd from top) and anti-ICER antibody (3rd and 4th from
top) after in vitro CHIP Ub ligase assay suggested that the Ub bands we observed in this
assay, especially above 120kDa, are mainly due to the ubiquitination of GST-ICER but not
from GST, IgG or endogenous CHIP as described in the method. (B) Quantifications of
relative CHIP Ub ligase activity from 3 independent experiments (mean±S.D., n=3, *p<
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0.05 compared to the Ad-LacZ and untreated control). Results were expressed as the relative
ratio of untreated cells in the LacZ control. (C) p90RSK activation inhibited ERK5-CHIP
association. Cardiomyocytes were transduced with Ad-DN-p90RSK or Ad-LacZ for 24 h,
followed by 45 min Ang II stimulation. Cell lysates were immunoprecipitated with anti-
CHIP, and immunoblotted with anti-ERK5. Expression of ERK5, CHIP and Flag-tagged
DN-p90RSK was detected by Western blotting using each specific antibody. (D) Relative
co-immunoprecipitated ERK5 band intensitites from 3 independent experiments were
quantified (mean±S.D., n=3, *p<0.05, compared to untreated control). Results are expressed
as fold decrease in ERK5 band intensity in Ang II-treated cells that are expressing either Ad-
LacZ or Ad-Flag-DN-p90RSK compared to untreated cells.
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Figure 3. CHIP Ub ligase activity and ICER expression after MI in diabetic DN-p90RSK-Tg
mice
(A) Heart samples from sham control and DM+MI groups in NLC mice and DM+MI group
in DN-p90RSK-Tg mice were collected and the CHIP Ub ligase activity assay was
performed as described in the Methods (top). Western blots showing in (A) CHIP, ICER,
and p90RSK, in (B) Bcl-2 and SERCA2, and in (C) p-(T218/Y220)ERK5, ERK5 and
tubulin expression. (D) Quantifications of relative CHIP Ub ligase activity and ICER
expression (upper) and the expression of Bcl-2 and SERCA2 (lower) (**p<0.01 *p< 0.05
compared to NLC sham operation control, mean±S.D., n=3,). Results are expressed as the
relative ratio of mean value of NLC sham operation.
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Figure 4. p90RSK kinase activation inhibits ERK5-CHIP association
(A, B) p90RSK-ERK5 and CHIP-ERK5 association were examined by a mammalian two-
hybrid assay in Hela cells. The activation domain VP16 fused to full length or three
truncated ERK5 proteins (A-B) and full length p90RSK (A) or CHIP (B) fused to the Gal4
binding domain were cotransfected with the Gal4-responsive luciferase reporter pG5-luc.
The total transfected DNA amount was normalized with empty VP16 vector. Binding
affinity was assayed by luciferase activity normalized by the renilla luciferase activity. Data
are representative of three independent experiments. **p<0.01, mean±S.D., n=3. (C) Both
wild type p90RSK (WT-p90RSK) and ERK5-Fr (aa571-807) but not DN-p90RSK disrupted
ERK5-CHIP association. After plasmid transfection as indicated, immunoprecipitated ERK5
was immunoblotted with anti-CHIP. Protein expression was determined by immunoblotting
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with each specific antibody. The blots are representative of data obtained from at least three
different blots. (D) Ang II increased p90RSK-ERK5 interaction via p90RSK activation.
Cardiomyocytes were stimulated with Ang II after 3h of FMK-MEA pre-treatment.
Immunoprecipitated ERK5 was immunoblotted with anti-p90RSK. Each protein expression
was detected as described in C. (E) Relative p90RSK-ERK5 binding was quantified as
described in Fig.2D. *p<0.05, mean±S.D., n=3.
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Figure 5. p90RSK phosphorylated ERK5-Ser496 and inhibited CHIP Ub ligase activity
(A) In vitro p90RSK kinase assay using 4 different GST-ERK5 fragments as substrates. An
autoradiogram (A, upper panel) shows strong 32P incorporation into a GST-ERK fragment
(aa401-600), and weak incorporation into another fragment (aa601-816). Ponceau staining
(A, lower panel) of the membrane demonstrates the position of proteins after separation by
SDS-PAGE. (B) LC-MS/MS analysis identified p90RSK-mediated ERK5-S496
phosphorylation with less than 0.05 error. An LC-MS/MS plot of different peptide
fragments shows S496 phosphorylation based on mass shift of phosphorylated serine with
H2O (+98 Da). The predicted mass of each b/y fragment and the actual value are shown
above with the b6 fragment containing the phosphorylated S496 having a predicted mass of
706.4 Da versus an actual value of 706.31 Da. (C) An error plot of the LC-MS/MS data
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shows the error for calculating each b/y peptide fragment is less than 0.5 Da. (D) Ang II-
mediated reduction of CHIP Ub ligase activity was inhibited by ERK5-S496A mutant.
Cardiomyocytes were transduced with either Ad-ERK5-WT, Ad-ERK5-S496A mutant, or
Ad-LacZ for 24 h followed by 2 h of Ang II stimulation as indicated. (E) Relative CHIP Ub
ligase activity was quantified as described in Fig.2B. (**p<0.01, *p<0.05, mean±S.D., n=3).
(F) Ang II-mediated ICER induction was inhibited by ERK5-S496A mutant.
Cardiomyocytes were transduced as described in D followed by 24 h of Ang II stimulation.
(G) Quantification of ICER expression as described in Fig.1B. (**p<0.01, *p<0.05, mean
±S.D., n=3).
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Figure 6. CHIP Ub ligase activity and ICER expression after MI in ERK5-CKO mice
(A) LV weight/tibial length (TL) and (B) lung weight/TL after MI in NLC and ERK5-CKO
mice as indicated (* p<0.05, mean±S.D., n=8-9). (C) Echocardiographic data obtained after
MI in NLC and ERK5-CKO mice as indicated. FS (fractional shortening), EF (ejection
fraction). (** p<0.01, mean±S.D., n=8-9) (D) Cardiomyocyte apoptosis in remote areas was
enhanced in ERK5-CKO mice. Animals were subjected to either MI or sham. TUNEL-
positive cardiomyocytes were counted among more than 8,000 to 10,000 nuclei in the
remote area of each mouse heart after one week of surgery. 40X objective lens. Scale bars,
40 μm. Representative pictures of TUNEL (top), 4’, 6’-diamidino-2-phenylindole (DAPI)
(middle), and α-actinin merged with TUNEL and DAPI staining (bottom) of the remote area
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from NLC and ERK5-CKO mice subjected to MI or sham operation as indicated. (E) A bar
graph showing TUNEL-positive cells (%) in various animals. (* p<0.05, mean±S.D.,
n=3-4). (F) Heart samples from sham and MI groups in NLC mice and in ERK5-CKO mice
were collected and CHIP Ub ligase activity assay was performed as described in methods
(top). CHIP, ERK5, ICER, and tubulin expressions were detected by Western blot. (G)
Relative CHIP Ub ligase activity (left, n=9) and ICER expression (right, n=3) were
quantified as described in Fig.2B and Fig.1B, respectively. (** p<0.01, * p<0.05, mean
±S.D.).
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Figure 7. ERK5 activation prevented the exacerbation of LV dysfunction after MI in WT-
p90RSK-Tg mice
(A) Kaplan-Meier survival analysis in NLC, WT-p90RSK-Tg, and Double-Tg-WT-
p90RSK-Tg/CA-MEK5α-Tg (Double-Tg) after MI. Survival rate in NLC (n=29), WT-
p90RSK-Tg (n=36), and Double-Tg mice (n=27) after MI are plotted. Overall survival was
significantly higher in Double-Tg compared to WT-p90RSK-Tg mice. * p<0.05 compared to
WT-p90RSK-Tg group. (B) Body weight one week after MI in NLC, WT-p90RSK-Tg, and
Double-Tg mice. (mean±S.D., n=17-19) (C, D) LV weight/TL (C) and lung weight/TL (D)
after MI in NLC, WT-p90RSK-Tg, and Double-Tg mice. (* p<0.05, ** p<0.01, mean±S.D.,
n=17-19) (E) Echocardiographic data obtained after MI in NLC, WT-p90RSK-Tg, and
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Double-Tg mice. LVEDd, left ventricular end-diastolic dimension; LVESd, left ventricular
endsystolic dimension; TL, Tibial length; FS (fractional shortening); EF (ejection fraction).
(* p<0.05, ** p<0.01, mean±S.D., n=17-19) (F) Cardiomyocyte apoptosis in the remote area
was increased in WT-p90RSK-Tg mouse hearts, which was inhibited in Double-Tg mice.
TUNEL-positive cardiomyocytes were counted in the remote area of each mouse heart as
described in Fig.6D. Representative pictures of TUNEL (top), DAPI (middle), and α-actinin
merged with TUNEL and DAPI staining (bottom) of the remote area from NLC, WT-
p90RSK-Tg, and Double-Tg mice subjected to MI or sham operation. 40X objective lens.
Scale bars, 40 μm (G) A bar graph showing TUNEL-positive cells (%) in various animals.
(** p<0.01, *p<0.05, mean± S.D., n=3).
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Figure 8. CHIP Ub ligase activity and ICER expression after MI in NLC, WT-p90RSK-Tg, and
Double-Tg mice
(A-C) Heart samples from control and MI groups in NLC, WT-p90RSK-Tg, and Double-Tg
mice were collected and CHIP Ub ligase activity assay was performed as described in
methods (top). Western blot shows (A) CHIP, ICER, p90RSK, p-ERK5, and ERK5 and (B)
Bcl-2, SERCA2, and tubulin expression. (C) Quantifications of relative CHIP Ub ligase
activity and ICER expression (upper), Bcl-2 and SERCA2 expression (lower) as described
in Fig.2B and Fig.1B. (**p<0.01, * p<0.05, mean±S.D., n=3). (D) A model of DM + MI or
Ang II-mediated p90RSK-ERK5-CHIP signal transduction pathway that regulates cardiac
apoptosis and subsequent cardiac dysfunction. (E) A scheme depicting p90RSK-mediated
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regulation of the ERK5-CHIP module. At the basal level, inactive p90RSK inhibits the D-
domain to bind with ERK539. p90RSK-free ERK5 associates with CHIP at its linker and U-
box domain and maintains its CHIP Ub ligase activity to prevent ICER induction and
subsequent apoptosis13. However, once p90RSK gets activated, the inhibition of the kinase
domain is released39, and the D-domain of p90RSK associates with the ERK5 COOH-
terminal domain, leading to compete with ERK5-CHIP association and ERK5-S496
phosphorylation, which disrupts ERK5-CHIP interaction. The disruption of ERK5-CHIP
interaction inhibits CHIP Ub ligase activity13, increases ICER induction, and induces
apoptosis13, 10.
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